[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Get more Watchlists, Portfolios, Custom Views and Chart Templates with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Royalty Pharma Plc Cl A (RPRX)

Royalty Pharma Plc Cl A (RPRX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Branded Pharmaceuticals Stocks Q1 Recap: Benchmarking Royalty Pharma (NASDAQ:RPRX)

Branded Pharmaceuticals Stocks Q1 Recap: Benchmarking Royalty Pharma (NASDAQ:RPRX)

RPRX : 52.96 (-1.38%)
Branded Pharmaceuticals Stocks Q1 Recap: Benchmarking Royalty Pharma (NASDAQ:RPRX)

Branded Pharmaceuticals Stocks Q1 Recap: Benchmarking Royalty Pharma (NASDAQ:RPRX)

RPRX : 52.96 (-1.38%)
3 Unpopular Stocks We’re Skeptical Of

3 Unpopular Stocks We’re Skeptical Of

RPRX : 52.96 (-1.38%)
BAX : 19.89 (+2.58%)
KFY : 71.46 (-0.29%)
Royalty Pharma (RPRX): Buy, Sell, or Hold Post Q1 Earnings?

Royalty Pharma (RPRX): Buy, Sell, or Hold Post Q1 Earnings?

RPRX : 52.96 (-1.38%)
Royalty Pharma to present at the Goldman Sachs 47th Annual Global Healthcare Conference

NEW YORK, June 04, 2026 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will participate in a fireside chat at the Goldman Sachs 47th Annual Global Healthcare Conference...

RPRX : 52.96 (-1.38%)
3 Mid-Cap Stocks We Steer Clear Of

3 Mid-Cap Stocks We Steer Clear Of

RPRX : 52.96 (-1.38%)
GDDY : 77.04 (+1.22%)
AMKR : 90.46 (+4.66%)
Royalty Pharma’s Q1 Earnings Call: Our Top 5 Analyst Questions

Royalty Pharma’s Q1 Earnings Call: Our Top 5 Analyst Questions

RPRX : 52.96 (-1.38%)
Royalty Pharma to present at upcoming investor conferences

NEW YORK, May 07, 2026 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will participate in the following upcoming investor conferences during the month of May: BofA...

RPRX : 52.96 (-1.38%)
Royalty Pharma reports first quarter 2026 results

Portfolio Receipts growth of 10% to $925 million; Royalty Receipts growth of 13% Net cash provided by operating activities of $718 million Raised full year 2026 guidance: Portfolio Receipts expected...

RPRX : 52.96 (-1.38%)
What Does Royalty Pharma's Revenue Forecast Say About the Royalty Model Itself?

Barchart Research What to Expect from RPRX Earnings RPRX Generated May 5, 2026 Current Price $50.44 EPS Estimate $$1.22 Consensus Rating Strong Buy Average Move 2.39% What Does Royalty Pharma's Revenue...

RPRX : 52.96 (-1.38%)

Barchart Exclusives

Dear MicroStrategy Stock Fans, Mark Your Calendars for July 4
Strategy investors are closely watching the July 4 CLARITY Act deadline, which could reshape crypto regulation and influence bitcoin-linked stocks. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.